



Date: May 5, 2021

The Secretary, Listing Department
BSE Ltd
P J Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 524735

The Manager, Listing Department
National Stock Exchange of India Ltd
Exchange Plaza,
Bandra-Kurla Complex, Bandra
Mumbai - 400 051.
Symbol: HIKAL

Dear Sir/Madam,

Sub.: 10-year multi-product contract with a leading global pharmaceutical innovator company

Ref.: Intimation under Regulation 30 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please find enclosed herewith, a copy of the press release regarding long term contract entered into by the Company with a leading global pharmaceutical innovator company.

Please treat this as an intimation under Regulation 30 of SEBI LODR.

Kindly take the above on your record.

For **Hikal Limited**,




Rajasekhar Reddy
Company Secretary & Compliance Officer

Hikal Ltd.

Admin. Office : Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. : +91-22-3097 3100. Fax : +91-22-2757 4277

Regd. Office : 717, Maker Chamber - 5, Nariman Point, Mumbai - 400 021, India. Tel. : +91-22-3926 7100, +91-22-6277 0477. Fax : +91-22-2283 3913

www.hikal.com info@hikal.com CIN : L24200MH1988PTC048028

PRESS RELEASE

Hikal signs a 10-year multi product deal with a leading global pharmaceutical innovator company

Mumbai, 5th May, 2021: Hikal Ltd., a preferred long-term partner for leading global life sciences companies, today announced that they have signed multi-year contract with a leading global pharmaceutical company. This contract entails the development and supply of a portfolio of niche APIs over a period of 10 years. The development will start this year and commercial supplies will commence post successful development and plant commercialisation estimated to be in FY 2024 onwards. With this deal, Hikal is entering into a niche area of chemistry and products thereby bolstering its Animal Health vertical. Hikal and its customer will be jointly investing at its Panoli, Gujarat site to setup a multipurpose manufacturing asset for manufacturing of these API's.

Commenting on this development, Mr. Sameer Hiremath, CEO, Hikal said, “We are very excited to be working with one of the leading global innovator pharmaceutical companies who have entrusted us to supply them with a strategic portfolio of APIs. We worked very closely with our customer to provide them a sustainable long-term competitive solution for their product portfolio from early-stage development to commercial supply. Hikal and our customer will be partnering in setting up a manufacturing facility to maintain security of supplies for the next ten years. We are seeing multiple opportunities from several new and existing customers who are looking to diversify and de-risk their existing supply chain.”

About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal's R&D facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects

of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company:	Investor Relations Advisors:
Hikal Limited	Strategic Growth Advisors Pvt. Ltd.
CIN: L24200MH1988PTC048028	CIN: U74140MH2010PTC204285
Mr. Anish Swadi	Mr. Jigar Kavaia
anish_swadi@hikal.com	jigar.kavaia@sgapl.net
	+91 9920602034
www.hikal.com	www.sgapl.net
